The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    幸运168飞艇官网 Deep Dive // Emerging biotech

    幸运飞行艇官方开奖历史记录-开奖记录查询 Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Sionna 幸运飞行艇官方开奖历史记录-开奖记录查询, a developer of cystic fibrosis drugs, could quickly follow Metsera and Maze Therapeutics and price an offering later this week.

    Updated Feb. 3, 2025
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip

    Shares of psychedelics biotech nearly double on depression data

    The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.

  • A Pfizer logo sits atop the entrance of the company's Ian C. Read Laboratories in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Pfizer drug acquired in $11B buyout confirms benefit in colon cancer

    The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb

    Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.

  • A bottle of Vertex Pharmaceuticals' new pain medicine Journavx.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

    Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit patients’ ability to access it.

    Updated Jan. 30, 2025
  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    幸运168飞艇官网 Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Atalanta is at least the third neuroscience-focused RNA drug developer to raise funds since October, while Helicore is the latest in a series of obesity investments by Versant Ventures.

    Updated Jan. 28, 2025
  • A sign spelling Nasdaq hangs on the side of a building while a pedestrian passes by.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Metsera, Maze secure combined $415 million in IPOs

    The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.

  • A Takeda logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Christophe Weber, veteran Takeda CEO, to retire next year

    Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

  • Robert F. Kennedy Jr., U.S. President Donald Trump’s nominee for Secretary of Health and Human Services departs after testifying in a confirmation hearing before the Senate Committee on Health, Education, Labor and Pensions at the Dirksen Senate Office Building on January 30, 2025 in Washington, D.C.
    Image attribution tooltip
    Kevin Dietsch/Getty Images via Getty Images
    Image attribution tooltip

    168体彩网飞艇历史数据精准计划 Jr. fumbles Medicare basics during second confirmation hearing

    In exchanges with senators Thursday, Robert F. Kennedy Jr. seemed unfamiliar with the particulars of the massive insurance program he'd oversee if confirmed as health secretary.

  • Trump executive orders, Akin Gump, executive order tracker
    Image attribution tooltip
    Anna Moneymaker / Staff via Getty Images
    Image attribution tooltip

    Trump administration affirms drug price talks, but will seek input to ‘improve’ program

    Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short CMS statement didn’t clear things up.

    Updated Jan. 30, 2025
  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    幸运168飞艇官网 Deep Dive

    Biotech M&A has plateaued. Track the deals that are happening here.

    Lantheus Holdings is paying $250 million to acquire Evergreen Theragnostics, a CDMO and developer of radiopharmaceutical drugs and diagnostics.

    Updated Jan. 28, 2025
  • A woman smiles for a photo taken inside a science laboratory
    Image attribution tooltip
    Permission granted by Cargo Therapeutics
    Image attribution tooltip

    Cargo to drop lead CAR-T therapy, lay off staff after study setback

    Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.

  • 23andMe
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    23andMe considers a sale as cash runs low

    The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.

  • Robert F. Kennedy Jr. speaks while sitting at a desk in a U.S. Senate building.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Democrats clash with RFK Jr. over vaccine views at heated Senate hearing

    Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of questioning vaccines.

    FDA
  • Robert F. Kennedy Jr. stands over a desk with his name tag.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    RFK Jr. signals he’ll back Trump abortion policies, despite prior stance

    At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, which is used in abortion and miscarriage care.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    幸运168飞艇官网 Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    Patents protecting Ibrance and Xtandi, two of the next 15 drugs Medicare selected for price talks, are set to expire by 2027, when any negotiated discount would take effect.

    Updated May 13, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    BioAge drops obesity drug; Akero, 89bio cash in on MASH data

    BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff. 

  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    FDA clears use of Ozempic to protect kidney health

    The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, which hasn’t yet proven it can improve outcomes in kidney disease. 

  • A droplet from a pipette hangs over a series of test tubes in this stock image.
    Image attribution tooltip
    K-Kwanchai via Getty Images
    Image attribution tooltip
    Obesity drugs

    Versant invests again in obesity, this time backing Helicore Biopharma

    Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.

  • Enhertu
    Image attribution tooltip
    Permission granted by Daiichi Sankyo
    Image attribution tooltip

    Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer

    The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety of tumors.

    FDA
  • An image of a periodic table entry for the chemical element lutetium
    Image attribution tooltip
    Lark Andrew Balcita via Getty Images
    Image attribution tooltip

    急速赛车168开奖网官方网站 168赛车的开奖官网历史查询结果 in trial, ITM says

    ITM's 一分钟极速赛车视频记录直播-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of neuroendocrine tumor.

  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Atalanta banks $97M to send RNAi drugs into the brain

    The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat conditions like Huntington’s.

  • A micrograph showing triglyceride fat accumulated inside liver cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Akero says MASH drug reverses liver damage in study, doubling shares

    Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.

  • A microscopic image of skeletal muscle tissue, stained red and purple.
    Image attribution tooltip
    Sinhyu via Getty Images
    Image attribution tooltip

    Muscle-building drug improves body composition in obesity trial, Veru says

    Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sage rebuffs Biogen bid to take it over

    Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to “maximize” shareholder value.